Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + veliparib
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline topoisomerase inhibitor), and veliparib (an oral poly(ADP-ribose) polymerase (PARP) inhibitor). Veliparib potentiates the effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. The combination has been studied in phase I clinical trials for advanced malignancies, particularly in metastatic breast cancer. The mechanism involves veliparib delaying repair of DNA damage induced by the chemotherapeutic agents, with increased DNA damage observed through markers like γH2AX in circulating tumor cells.
02
Targets
DNATOP2A (DNA topoisomerase II)PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + veliparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + veliparib.